An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

Launched by CHANGHAI HOSPITAL · Aug 23, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for patients with a condition called systemic lupus erythematosus (SLE), which can cause a range of symptoms and affect multiple organs in the body. The treatment being tested involves using special cells, known as anti-CD19 CAR NK cells, to see if they are safe and effective for individuals who have moderate to severe SLE that hasn't responded well to other therapies. The study aims to enroll 9 to 12 patients aged 18 to 65 who have a confirmed diagnosis of SLE and meet specific health criteria.

Participants in the trial will receive the experimental treatment and will be monitored closely for safety and effectiveness. They should be aware that they cannot have certain health conditions, such as severe allergies or active infections, and females who can become pregnant must use effective contraception during the study. This is an early-phase study, meaning it is one of the first steps in testing this treatment, and the results could help shape future therapies for SLE. If you or a loved one is considering participation, it’s important to discuss this option with your healthcare provider to understand the potential benefits and risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age: ≥ 18 years old and ≤ 65 years old, male or female, subjects voluntarily participate in this clinical study and sign the Informed Consent Form (ICF)
• • 2. Previous diagnosis of systemic lupus erythematosus (SLE) (according to the 1997 American Rheumatology Association criteria)
• • 3. Females of childbearing potential must use effective contraception during study treatment and for 90 days after the last dose of study treatment. In addition, subjects must not donate eggs during the study and for at least 90 days after the last dose of study treatment
• • 4. Subjects with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score ≥ 8 points prior to screening
• • 5. Subject has ≥ 1 organ system with BILAG-2004 Class A mobility score or ≥ 2 organ systems with BILAG-2004 Class B mobility score prior to screening
• 6. Subjects meets one of the following:
• • 1. Antinuclear antibody (ANA) ≥ 1:80, determined by immunofluorescence method;
• • 2. Anti-dsDNA antibodies are higher than normal level;
• • 3. Anti-Smith antibodies are higher than normal level
• • 7. Absolute number of neutrophils ≥ 1.0×10\^9/L, hemoglobin ≥ 60g/L
• • 8. Left ventricular ejection fraction (LVEF) ≥ 50%
• • 9. Subjects have been treated with oral corticosteroids (OCS) in combination with an immunosuppressive or biologic agent for at least 6 months prior to enrollment
• Exclusion Criteria:
• • 1. Subjects with known severe allergic reactions, hypersensitivity, contraindication to any medications during the trial (cyclophosphamide, fludarabine, obinutuzumab), or subjects with a history of severe allergic reactions
• • 2. Subjects with active infection receiving intravenous (IV) antibiotic treatment, or received intravenous (IV) antibiotic treatment within one week prior to anti-CD19 CAR NK Cells infusion
• • 3. Subjects with acquired and congenital immunodeficiency diseases
• • 4. Subjects with grade III or IV heart failure (NYHA classification)
• • 5. History of epilepsy or other central nervous system (CNS) diseases
• • 6. History of severe herpetic infection, such as herpetic encephalitis, ocular herpes, or diffuse herpes
• 7. History of other primary malignant tumors except:
• • 1. Cured non-melanoma skin cancer by surgical excision, for example basal cell carcinoma (BCC) ;
• • 2. Cured primary malignant tumors, such as cervical cancer, superficial bladder cancer, breast cancer
• • 8. Signs of herpes or varicella-zoster virus infection (especially chickenpox, shingles) within 12 weeks prior to screening; History of any cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal disease or other major medical condition that would prevent the administration of anti-CD19 CAR NK Cells (KN5501), except for lupus (determined by the investigator)
• • 9. Females who are pregnant, lactating, or planning a pregnancy within six months
• • 10. Any active skin disease that may interfere with the study assessment of SLE, including but not limited to psoriasis, dermatomyositis, systemic sclerosis, non-LE cutaneous lupus manifestations (eg, cutaneous vascular disease, periungual telangiectasia, fingertip sclerosis, rheumatoid nodules, erythema multiforme, leg ulcers) or drug-induced lupus
• • 11. Subjects who have received other clinical trial treatment within 3 months
• • 12. Subjects who have received B cell-targeted drug therapy within 1 month before enrollment
• • 13. Any abnormal laboratory test results judged by the investigator to be clinically significant and prevent the subject from participating in the study. Laboratory test values that are out of range and not of clinical significance will not be considered as exclusion criteria
• • 14. Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome